In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding ...

A 2025 report from a bipartisan, congressionally chartered commission warns that China is closing in on a win, and the United ...

At September 30, 2025, Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million. Subsequent to the fiscal year end, the company received $3.4 million in net proceeds, ...

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through ...

A drug launch is one of the most defining events in the pharma and biotech lifecycle. It marks the moment a therapy moves from years of research and clinical testing into real world availability for ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

The coming era of biosecurity will demand a broader and more adaptive approach as AI, powerful biological engineering ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, ...

The incidence of HPV16-related cancers is rapidly increasing in the US and Europe and also increasing globally.* PDS0101 is currently being studied in the Company’s Phase 3 trial for PDS0101 + ...

With regulators across Asia-Pacific easing pathways for new therapies, Dimerix is positioning DMX-200 for one of the world’s ...